Valuation: Transgenomic Inc

Market Cap 47.37M 41.31M 39M 35.42M 66.36M 4.55B 66.63M 467M 180M 2.31B 178M 174M 7.44B P/E 2024
-1.89x
P/E 2025 -102x
Enterprise Value 48.37M 42.18M 39.83M 36.17M 67.76M 4.64B 68.04M 477M 184M 2.36B 182M 178M 7.59B EV / Sales 2024
0.44x
EV / Sales 2025 1.72x
Free-Float
87.32%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Operating Officer 41 -
Chief Tech/Sci/R&D Officer 42 01/06/2017
Chief Executive Officer 54 28/06/2017
Director TitleAgeSince
Director/Board Member 54 28/06/2017
Director/Board Member 78 26/09/2017
Director/Board Member 67 08/11/2017
Change 5-day change 1-year change 3-year change Capi.($)
+2.18%+10.75%+20.36%-20.90% 17.65B
+0.57%+7.59%-40.66%+36.28% 1.89B
+0.50%-1.62%-33.13%+25.09% 870M
-0.27%+0.16%+50.57%+1.04% 779M
-4.24%-9.85%-63.10%-85.54% 728M
+1.13%+0.56%-35.58%-50.30% 642M
-0.97%-1.08%-43.59%-54.34% 555M
+1.98%+1.66%-42.93%-36.36% 439M
-4.10%+10.61%+44.25%+74.34% 435M
Average -0.38%+0.93%-15.98%-12.30% 2.67B
Weighted average by Cap. +1.49%+4.83%+8.37%-16.10%

Financials

2024 2025
Net sales 18.53M 16.16M 15.26M 13.86M 25.96M 1.78B 26.07M 183M 70.53M 904M 69.62M 68.07M 2.91B 24.05M 20.97M 19.8M 17.98M 33.69M 2.31B 33.83M 237M 91.53M 1.17B 90.34M 88.33M 3.77B
Net income -4.29M -3.74M -3.53M -3.21M -6.01M -412M -6.03M -42.31M -16.33M -209M -16.12M -15.76M -673M -363K -317K -299K -271K -509K -34.83M -511K -3.58M -1.38M -17.71M -1.36M -1.33M -56.98M
Net Debt -136K -119K -112K -102K -191K -13.05M -191K -1.34M -518K -6.63M -511K -500K -21.35M 1M 874K 825K 749K 1.4M 96.15M 1.41M 9.88M 3.81M 48.88M 3.76M 3.68M 157M
Logo Transgenomic Inc
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
Employees
-
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!